Crosslink Therapeutics
Crosslink Therapeutics Inc.
Crosslink leads in genetic research and solutions, offering cutting-edge innovations to revolutionize healthcare and transform lives through genetics.
xlinktx.com · Boston, MA
Funding event
The round itself, as filedInferred stageSeed
Sold of offered$5.5M of $5.5M
Filed2026-10-20
Days since filing24
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-10-08
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Ronald D. Seidel, IIIExecutive Officer · Director
- Andrew KingDirector
- Lou TartagliaDirector
- Rodolfo ChaparroDirector
- David FallaceDirector
- Cameron GallagherDirector
Health flags
Three flags, each with the raw inputs behind it · as of 2026-11-13UndersubscribedNot flagged$5.5M of $5.5M sold1.2 months since first sale
Prior raiseNot flaggedRaised $5.5M against a prior $4.3M$4.3M prior raise, filed 2025-05-15
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-10-310
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
No open roles foundWe read careers pages daily.
Also raised in Health & bio
Same sector, 28 days to 2026-11-15OrcosaSeries A · $6.0M of $11.5M · Ewing, NJQuietChronicleBioPre-seed · $250K of $1.0M · Menlo Park, CAQuiet
103 rounds in Health & bio in the 28 days to 2026-11-12, against 122 in the 28 days before.